Expression Of RASSF1A MRNA In Transitional Cell Carcinoma Of The Bladder

Objective: To investigate the expression and clinical significance of RASSF1A mRNA in carcinoma tissues and normal bladder tissues of the patients with transitional cell carcinoma of the bladder(TCCB). Methods: RASSF1A mRNA in T24 bladder cancer cell line, carcinoma tissues and normal bladder tissues of 48 patients with TCCB were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The data was analyzed with SPSS 10.0 software. Results: 1. The expression of RASSF1A mRNA showed negative in T24 bladder cancer cell line. 2. Among 48 patients with TCCB, 29 patients (60.42%)showed negative expression of RASSF1A mRNA in carcinoma tissues ,while 48 patients showed positive expression of RASSF1A mRNA in normal bladder tissues,the negative expression rate of RASSF1A mRNA was 0.00%. The RASSF1A mRNA expression difference between normal bladder tissues and carcinoma tissues was significant (χ² test, P<0.05). 3. The expression of RASSF1A mRNA in the clinicopathological features of TCCB: According to the standard of WHO, the negative rate of RASSF1A mRNA expression in G₁ was 35.71%(5/14), G₂ 63.64%(14/22), G383.33%(10/12). According to the standard of UICC, the negative rate of RASSF1A mRNA expression in PT1 was 35.71%(5/14), PT₂^T₄ 70.59%(24/34). The expression difference of RASSF1A mRNA was significant in the different grade or stage (χ² test, P<0.05). 4.The expression of RASSF1A mRNA in patients of TCCB with different clinical features : Expression of RASSF1A mRNA in 17 patients with carcinoma diameter less than 2cm in diameter, 9 patients (52.29%) showed negative expression and 8 showed positive expression; in other 31 patients whose carcinoma diameter was more than 2cm,, 21 patients (64.52%) showed negative expression and 10 showed positive expression. Expression of RASSF1A mRNA in solitary tumor and multiple tumor: among 33 solitary tumor patients, 18 showed negative expression and 15 showed positive expression, the negative expression rate of RASSF1A mRNA expression was 54.55%; among 15 multiple tumor patients, 11 showed negative expression and 4 showed positive expression, the negative expression rate of RASSF1A mRNAexpression was 73.33%. Expression of RASSF1A mRNA in primary tumor and recurrence tumor: among 35 patients with primary tumor , 20 patients (57.14% )showed negative expression and 15 showed positiveexpression ; among 13 patients(69.23%) with recurrence tumor patients, 9 showed negative expression and 4 showed positive expression, the negative expression rate of RASSF1A mRNA was 69.23%. The expression difference of RASSF1A mRNA was not significant in the tumor of different clinical features (χ² test, P>0.05). 5. The expression of RASSF1A mRNA in 48 patients of TCCB with different gender and age : the negative rate of RASSF1A mRNA in patients with different gender: among 40 male patients, 24 (60.00%)showed negative expression and 16 showed positive expression; among 8 female patients, 3(37.50%) showed negative expression and 5 showed positive expression. The expression of RASSF1A mRNA in different ages : among 26 patients younger than 60 years old, 15(57.69%) showed negative expression and 11 showed positive expression;among 22 patients older than 60, 14 (63.63%)showed negative expression and 8 showed positive expression. The expression difference of RASSF1A mRNA was not significant in 48 patients of TCCB with different gender and age (χ² test, P>0.05). Conclusions: 1. Carcinoma tissues of the patients with TCCB showed significantly negative expression of RASSF1A mRNA.the deletion of RASSF1A mRNA expression may be associated with occurrence and development of TCCB. 2. The deletion of RASSF1A mRNA may beassociated with the stages and grades of TCCB. The deletions of RASSF1A mRNA may accelerate malignant progress of tumor. 3. Deletion of RASSF1A mRNA expression may have no ralationship with the patients' gender ,age, size of carcinoma,and general clinical features of TCCB.